© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
January 09, 2021
Using piperacillin/tazobactam increases the risk for acute kidney injury, and this risk can be exacerbated by concurrent vancomycin.
January 08, 2021
If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.
January 05, 2021
Patients who continue RAS therapy had a lower risk of kidney replacement therapy.
January 04, 2021
The SGLT2 inhibitor demonstrated possible erythropoietic effects in type 2 diabetes patients.
December 29, 2020
The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.
December 21, 2020
FibroGen will submit additional data for the New Drug Application.
December 15, 2020
There was not a statistically significant difference in eGFR between kidney recipients of HCV positive and negative donors.
December 09, 2020
Dr. Gerald Shulman discusses how diabetes can eventually be reversed.
By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.
Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.